Acute Lymphoblastic Leukemia Treatment with Vincristine – Phase III

Intensive Treatment For Intermediate-Risk Relapse Of Childhood B-Precursor Acute Lymphoblastic Leukemia: A Randomized Trial Of Vincristine Strategies

Protocol Description

The primary goal of this Children’s Oncology Group Phase III study is to establish an effective therapy for treatment of acute lymphoblastic leukemia (ALL) that has relapsed, using a treatment plan calling for higher and, in some cases, more frequent dosages of methotrexate, cytarabine and vincristine than the standard dosages.

Study Level: Phase III

Eligibility Criteria

Subject to certain exclusion criteria, the study is open to individuals of both genders, from age 1 through 21, who have intermediate-risk relapsed ALL.
Males: Ages 1 through 21 years
Females: Ages 1 through 21 years

Participants will be randomly assigned to either of 2 groups – standard therapy or experimental therapy. The treatment plan involves chemotherapy and may include ratiation therapy. Treatment is divided into 7 stages: Induction 1; Induction 2; Induction 3; Intensification 1; Re-induction; Intensification 2 and Maintenance. Some participants may receive a bone marrow tranplant after Induction 3 rather than receive the rest of the chemotherapy treatment.
Duration: About 27 months

Status: Open for Enrollment

Source(s) of Support
Children’s Oncology Group (Study AALL0433)
National Cancer Institute
Third Party

Additional Resources
Study Description at National Institutes of Health

Primary Investigator(s)

A. Kim Ritchey, MD

Contact Information

For additional information, please contact:
Jill Visnich

Last Update
February 17, 2014
  • Increase/Decrease Text Size
  • Print This Page
Last Update
February 17, 2014